# LUMINA

Source: https://onco.cc/trials/lumina/  
OnCo record `lumina` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

LUMINA used tumour biology, not just age, to pick women who can skip breast radiotherapy: with a luminal A profile and endocrine therapy, local recurrence at five years was about two percent.

## Summary

LUMINA was a single-arm prospective study of 500 women aged 55 or older with grade 1 or 2 T1N0 luminal A breast cancer (oestrogen and progesterone receptor-positive, HER2-negative, Ki67 of 13.25 percent or less) who had breast-conserving surgery and endocrine therapy and no radiotherapy. Five-year local recurrence was 2.3 percent, 90 percent confidence interval 1.3 to 3.8 (Whelan and colleagues, New England Journal of Medicine 2023;389:612 to 619), supporting biomarker-based omission.

## Fields

- Kind: Trial
- Status: positive
- Last checked: 2026-09-16
- Tags: radiation-wave2
- Registry id: NCT01791829
- Phase: 2
- Setting: Women aged 55 or over with small luminal A breast cancer after breast-conserving surgery and endocrine therapy: radiotherapy omitted
- Sponsor: Ontario Clinical Oncology Group
- Enrolled: 500
- Result: 5-year local recurrence 2.3% without radiotherapy in luminal A disease.
- Outcomes: Local recurrence at 5 years: Endocrine therapy, no radiotherapy 2.3%

## Sources

- ClinicalTrials.gov NCT01791829: https://clinicaltrials.gov/study/NCT01791829
- Whelan et al., New England Journal of Medicine 2023;389:612 to 619: omitting radiotherapy after breast-conserving surgery in luminal A breast cancer: https://doi.org/10.1056/NEJMoa2302344

## Connected records

- cancers: [Breast cancer (all types)](https://onco.cc/cancers/breast-cancer/), [HR-positive / HER2-negative breast cancer](https://onco.cc/cancers/breast-hr-positive/)
- technologies: [Active surveillance](https://onco.cc/technologies/active-surveillance/)
- companies: [Ontario Clinical Oncology Group](https://onco.cc/companies/ocog/)
- terms: [Leaving radiotherapy out](https://onco.cc/terms/radiotherapy-omission-early-breast-cancer/)
- trials: [CALGB 9343](https://onco.cc/trials/calgb-9343/), [PRIME II](https://onco.cc/trials/prime-ii/)
- key papers: [Omitting Radiotherapy after Breast-Conserving Surgery in Luminal A Breast Cancer](https://onco.cc/key-papers/paper-lumina-n-engl-j-med-2023/), [γ-Secretase inhibitor in combination with BCMA chimeric antigen receptor T-cell immunotherapy for individuals with relapsed or refractory multiple myeloma: a phase 1, first-in-human trial](https://onco.cc/key-papers/paper-cowan-lancet-oncol/)

---
JSON: https://onco.cc/api/v1/entities/lumina.json